Boston Scientific Corporation

1468 articles with Boston Scientific Corporation

• Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

  5/22/2019

  Findings could expand number of patients who can receive alternative treatment to life-long use of blood thinners

• SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX

  5/14/2019

  Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation and certain of its officers.

• Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific EMBLEM™ S-ICD System

  5/10/2019

  New data further support use of S-ICD System as first-line therapy for majority of ICD patients

• Boston Scientific Announces Agreement To Acquire Vertiflex, Inc.

  5/9/2019

  Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies

• Latham & Watkins Advises Boston Scientific in its Acquisition of Vertiflex

  5/9/2019

  Boston Scientific (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the Superion® Indirect Decompression System,

• Boston Scientific to Participate in the 2019 UBS Global Healthcare Conference

  5/7/2019

  Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City.

• Boston Scientific Receives U.S. FDA Approval for The VICI VENOUS STENT™ System

  5/6/2019

  New Stent System Now Available for Treating Patients with Deep Venous Blockages

• Boston Scientific to Participate in Bank of America Merrill Lynch Healthcare Conference 2019

  5/1/2019

  Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas.

• Boston Scientific Announces Scheduled Presentations at Heart Rhythm 2019

  5/1/2019

  Boston Scientific Corporation announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May 8-11.

• Boston Scientific Corp. Shareholder Alert: Securities Lawsuit Filed Against BSX

  4/26/2019

  Thornton Law Firm LLP announces that it is investigating a securities class action on behalf of shareholders and investors who purchased the securities of Boston Scientific Corporation.

• Johnson Fistel Announces Class Action Suit against Boston Scientific Corporation (BSX); Encourages Investors to Contact the Firm for Additional Information

  4/25/2019

  Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Boston Scientific Corporation on behalf of all purchasers of common stock during the period between February 26, 2015 through April 16, 2019, inclusive.

• Boston Scientific Announces Results For First Quarter 2019

  4/24/2019

  Boston Scientific Corporation generated sales of $2.493 billion during the first quarter of 2019.

• Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

  4/23/2019

  Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment

• Boston Scientific Announces Conference Call Discussing First Quarter 2019 Financial Results

  3/27/2019

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24, 2019 at 8:00 a.m. EDT.

• Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter

  3/17/2019

  New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology

• Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

  3/11/2019

  Boston Scientific Corporation announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal, on March 17-19.

• VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD

  3/9/2019

  VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.

• Boston Scientific to Participate in the Cowen and Company 39th Annual Healthcare Conference

  2/27/2019

  Boston Scientific Corporation will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston.

• Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes

  2/25/2019

  Boston Scientific Corporation completed a public offering of $4.3 billion aggregate principal amount of its senior notes.

• Boston Scientific Prices $4.3 Billion of Senior Notes

  2/21/2019

  Boston Scientific Corporation announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration statement.